1. Home
  2. AUST vs CMMB Comparison

AUST vs CMMB Comparison

Compare AUST & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Austin Gold Corp.

AUST

Austin Gold Corp.

SELL

Current Price

$0.53

Market Cap

13.3M

Sector

N/A

ML Signal

SELL

Logo Chemomab Therapeutics Ltd.

CMMB

Chemomab Therapeutics Ltd.

SELL

Current Price

$1.22

Market Cap

10.9M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
AUST
CMMB
Founded
2020
2004
Country
Canada
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.3M
10.9M
IPO Year
2021
2023

Fundamental Metrics

Financial Performance
Metric
AUST
CMMB
Price
$0.53
$1.22
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
★ $15.00
AVG Volume (30 Days)
22.8K
★ 59.0K
Earning Date
11-05-2026
11-19-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 101.67
EPS
N/A
★ 0.04
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
$28.00
Revenue Growth
N/A
N/A
52 Week Low
$0.58
$0.92
52 Week High
$3.92
$2.99

Technical Indicators

Market Signals
Indicator
AUST
CMMB
Relative Strength Index (RSI) 24.58 43.53
Support Level N/A $0.99
Resistance Level $1.43 $1.91
Average True Range (ATR) 0.08 0.19
MACD -0.01 0.02
Stochastic Oscillator 0.00 20.74

Price Performance

Historical Comparison
AUST
CMMB

About AUST Austin Gold Corp.

Austin Gold Corp is focused on the acquisition, exploration, and evaluation of mineral resource properties in the western United States of America (USA). The exploration and development of mineral projects is considered the Company's single business segment. Its projects include Kelly Creek, Lone Mountain, Stockade Mountain, Fourmile Basin, and Miller.

About CMMB Chemomab Therapeutics Ltd.

Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.

Share on Social Networks: